We are single-minded in our pursuit of a cure for Glioblastoma Multiforme (GBM), and invite you to explore our Investor Relations page to understand the financial promise that aligns with our life-changing mission.

Nasdaq: CNSP View Details
0.11 USD
0 (-1.12%)
1742.0k Volume
CNS Pharmaceuticals December 12, 2024 3:00 PM EST

New Releases

View All
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis...
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025HOUSTON, TX / ACCESSWIRE / November 25,...

Events

View All
Dec 11 2024 11:30 AM EST

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day

Nov 22 2024 8:30 PM - 10:30 PM EST

Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)

Sep 09 2024 7:00 AM EDT

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Stay Updated
At least one type of alert must be selected.
An email address is required.

Your email alerts were set.

The following alerts could not be set:

Resources

CNSP Investor Presentation PDF
01 August, 2024

Analyst Coverage

Jason McCarthy, PhD Maxim Group

CNS Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding CNS Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CNS Pharmaceuticals, Inc. or its management. CNS Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Company

Management Team View
SEC Filings View
Events and Presentations View
FAQ View
Contact IR View

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Additionally, the Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.